All Assays articles – Page 10
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
WebinarFunctional assays for the development of agonistic antibodies
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
-
WebinarComplete CAR-T workflow solutions for research
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
-
WhitepaperCase study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
-
WhitepaperApplication note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
-
Whitepaperebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
-
WebinarCardiac and vascular safety liabilities using totality of evidence approach
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.
-
Whitepaperebook: Choosing the right assay for PARP
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
-
WebinarInnovations in organoid modelling for disease modelling and cell therapy
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
-
WhitepaperBrochure: Overcome roadblocks in your PROTAC characterizations with Dianthus
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
-
VideoVideo: Using luciferase reporter cell lines for HTS readouts
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery.
-
WebinarNormalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay
A discussion of the recently published paper, “Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation-based Assay,” and how the field can produce more replicable experiments.
-
Whitepaperebook: Quantitative Assays to Measure Ab Binding to Fc Receptors
This ebook summarizes the basics of Fc receptor function and discusses biochemical and cell-based assays that enable antibody optimization projects.
-
Whitepaperebook: TR-FRET assay kits simplify & accelerate drug discovery
This ebook provides basic principles of the TR-FRET technology and shows examples of how assay design can drive drug discovery.
-
WebinarAccelerating biologics discovery via antibody library and reaching IND faster with cell line development
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
-
VideoWebinar: The Role of Neuronal Metabolism in Early Drug Discovery
Learning about the mitochondrial role in a neurodegenerative disorder.
-
Article
Assay performance and the Z’-factor in HTS
Matthew Lloyd from the University of Bath reveals the importance of the Z-factor and Z’-factor in high-throughput screening, and how they can be used to determine assay performance, perform quality control on the screen, and identify active compounds.
-
ArticleDe-risking drugs in multiplex assays before progressing to clinical trials
Sheraz Gul, Head of Assay Development and Drug Repurposing at the Fraunhofer Institute, discusses the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research to decrease the risk of potentially undesirable events in later clinical studies.